International Scientific Webinar

Thursday, 29th April 2021, 13.00-16.20 (CEST) (07.00-10.20 EDT)

On 11 March 2021, the Danish Health Authority suspended the use of the AstraZeneca COVID-19 vaccine (Vaxzevria®) pending national and international investigations into safety signals. “In the following four weeks, a new syndrome was described (Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), causality was established and a Danish-Norwegian registry study that the estimated the excess of VITT following Vaxzevria® as 1 per 40.000 vaccinated. Based on these findings, and a contextual assessment of the current Danish epidemic, on 14 April 2021 the Danish Health Authority decided to continue vaccine roll-out in Denmark without Vaxzevria® within the national COVID-19 vaccine program.

The aim of this webinar is to share insights and considerations in a transparent manner. Thus, the webinar will present the latest information on the epidemiology, possible pathophysiology, diagnosis, treatment and public health implications of VITT.

Each session consists of comprehensive presentations followed by discussion, which is moderated by experts.

Programme

During the 3-hour virtual webinar, comprehensive presentations will be followed by discussions, which will be moderated by the respective experts.

Information about the speaker can be found on the streaming site.

Registration is required, but the webinar is open to all, free of charge.

How to join the live broadcast.

On entering the site, you will be first prompted to accept the Terms & Conditions of use.

You will be asked to enter your email address, and once submitted, you will immediately receive an email with an activation code. Enter the activation code and your name and you will enter the live platform.

Please register here

13.00-13.05	Welcome Søren Brostrøm, MD, PhD, MPA, Director General, Danish Health Authority, Denmark

13.05-14.00	Session 1: Discovery of the adverse events Introduction to the theme and purpose of the webinar Chair: Anne Mette Hvas, Professor, MD, PhD, Deputy Head of Department, Aarhus University, Denmark

	The Danish experience: reactions by the authorities, scientific investigations, and public health reflections Søren Brostrøm, MD, PhD, MPA, Director General, Danish Health Authority, Denmark Pharmaco-epidemiological investigations within the Norwegian and Danish cohort Anton Pottegård, Professor, MSc, PhD, University of Southern Denmark The German experience Andreas Greinacher, Professor, MD, DMSc. University of Greifswald, Germany Panel discussion Session speakers including Beverly J. Hunt, Professor, MD, King’s College London, UK.

14.00-14.05	Break

14.05-14.50	Session 2: Clinical care perspectives on vaccine-induced immune thrombotic thrombocytopenia (VITT) Chair: Lars Østergaard, Clinical Professor, MD, PhD, Chief Physician, Chair, Aarhus University, Denmark

	Proposed case-definition of VITT and treatment algorithm Jakob Stensballe, Senior Consultant, MD, PhD, Rigshospitalet, Denmark Biomarker investigations and genetic studies Sisse Rye Ostrowski, Professor, MD, PhD, DMSc and Chief Physician , Rigshospitalet and University of Copenhagen, Denmark Panel discussion: State-of-the-art diagnosis & treatment of VITT Anne Mette Hvas, Professor, MD, PhD, Deputy Head of Department, Aarhus University, Denmark Jakob Stensballe, Senior Consultant, MD, PhD, Rigshospitalet, Denmark Sisse Rye Ostrowski, Professor, MD, PhD, DMSc and Chief Physician, Rigshospitalet and University of Copenhagen, Denmark Andreas Greinacher, Professor, MD, DMSc., University of Greifswald, Germany Beverly J. Hunt, Professor, MD, King’s College London, UK.

14.50-14.55	Break

14.55-15.25	Session 3: The importance of different adenovirus vectors in VITT Chair: Jens Lundgren, Professor, MD, DMSc, Senior Consultant, Academic Chair, Director, Rigshospitalet and University of Copenhagen, Denmark

	US-experience from the rollout of the J&J vaccine Narayan Nair, MD, Division Director, Division of Epidemiology, FDA, USA Discussion Jens Lundgren, Professor, MD, DMSc, Rigshospitalet and University of Copenhagen, Denmark Narayan Nair, MD, Division Director, Division of Epidemiology, FDA, USA

15.25-15.30	Break

15.30-16.15	Session 4: Difficult dilemma: the public health benefits versus risks Chair: Jesper Hallas, Professor, MD, Dr.Med.Sc, University of Southern Denmark

	What can economics contribute with? Trygve Ottersen, MD, PhD, Director, Management and Staff for Health Services, Norwegian Institute of Public Health, Norway Panel discussion Siddhartha Datta, MD, MPH, Regional Adviser, Vaccine Preventable Diseases and Immun-ization, WHO Europe Georgy Genov, MD, Head of Pharmacovigilance Office, within Quality and Safety of Medi-cines Department, European Medicines Agency, EMA Camilla Stoltenberg, MD, PhD, Direc-tor General, Norwegian Institute of Public Health, Norway Søren Brostrøm, MD, PhD, MPA, Director General, Danish Health Authority, Denmark

16.15-16.20	Closing remarks Søren Brostrøm, MD, PhD, MPA, Director General, Danish Health Authority, Denmark

Please register here

Danish Health Authority Islands Brygge 67
2300 Copenhagen S

www.sst.dk